To investigate the combination effects of Mosun‐Pola, we used two germinal center B‐cell‐like (GCB) type human DLBCL cell lines, SU‐DHL‐8 and HT cells, which were refractory to polatuzumab vedotin. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.